

# EXHIBIT 6

UNITED STATES DISTRICT COURT  
DISTRICT OF MASSACHUSETTS

-----X

UNITED STATES OF AMERICA  
ex rel. JULIE LONG,  
Plaintiffs,

vs.

JANSSEN BIOTECH, INC.,  
Defendant.

Civil Action No.: 16-12182-FDS

-----X

VIDEOTAPED DEPOSITION OF JANICE BABIA-RAMOS  
Tuesday, December 19, 2023  
Conducted Remotely

REPORTED BY:  
Christina Diaz, CRC, CRR, RMR, CSR-NY/NJ, CLR  
HUDSON COURT REPORTING & VIDEO (800) 310-1769

## A P P E A R A N C E S

COHEN, MILSTEIN, SELLERS & TOLL, PLLC  
Attorneys for Plaintiff Relator Julie Long:

3 Logan Square  
1717 Arch Street, Suite 36  
Philadelphia, PA 19103  
267.479.5700

cpreston@cohenmilstein.com

BY: CASEY M. PRESTON, ESQUIRE  
- and -

11780 U.S. Highway One, Suite N500  
Palm Beach Gardens, FL 33408  
561.515.1400

prazavi@cohenmilstein.com  
tleopold@cohenmilstein.com

BY: POORAD RAZAVI, ESQUIRE  
THEODORE J. LEOPOLD, ESQUIRE  
- and -

Two Logan Square  
100-120N 18th Street, Suite 1820  
Philadelphia, PA 19102

atoric@cohenmilstein.com

BY: ADNAN TORIC, ESQUIRE

1  
2  
3  
4  
5  
6  
7 December 19, 2023  
8 9:04 A.M. E.S.T.  
9  
10 Videotaped deposition of JANICE  
11 BABIA-RAMOS, taken by plaintiffs, pursuant  
12 to notice dated December 11, 2023, conducted  
13 remotely, before Christina Diaz, a Certified  
14 Realtime Captioner, Certified Realtime and  
15 Registered Merit Reporter and Notary Public  
16 within and for the State of New York.  
17  
18  
19  
20  
21  
22  
23  
24  
25

## A P P E A R A N C E S (Cont'd.)

COVINGTON & BURLING, LLP  
Attorneys for Defendants and  
Witness Janice Babia-Ramos

One City Center  
850 Tenth Street, N.W.  
Washington, D.C. 20001-4956  
202.662.6000

jraofield@cov.com

mdunn@cov.com

adiciurcio@cov.com

npastan@cov.com

nbaer@cov.com

BY: NICHOLAS PASTAN, ESQUIRE  
JASON C. RAOFIELD, ESQUIRE  
MATTHEW F. DUNN, ESQUIRE  
NICHOLAS BAER, ESQUIRE  
ALISON DiCIURCIO, ESQUIRE

ALSO PRESENT:  
EDWIN MENDEZ, Videographer

Page 185

1 J. Babia-Ramos  
 2 Q. Were your communications with the  
 3 PRC done through telephone discussions, a  
 4 live meeting or via e-mail, or a  
 5 combination of those three?  
 6 A. So it would be a combination.  
 7 But mostly in person, like physically in  
 8 the meetings.  
 9 And what I mean by a combination  
 10 is, sometimes one of the members on the  
 11 team would have to call in to be part of  
 12 the meeting.  
 13 Q. And where did the meetings take  
 14 place?  
 15 A. Home office.  
 16 Q. In a conference room?  
 17 A. Yes. In a conference room.  
 18 Q. And then as the project  
 19 initiator, you would present the strategy  
 20 or program that you wanted the PRC to  
 21 review?  
 22 A. As the project initiator, I was  
 23 responsible for shepherding that item  
 24 through PRC, going back and making any  
 25 edits if they recommended any edits and

Page 186

1 J. Babia-Ramos  
 2 bringing it back through PRC until final  
 3 approval.  
 4 Q. In the context of the site of  
 5 care 360 support strategy, do you recall  
 6 that the PRC asked you to make changes to  
 7 your submission?  
 8 MR. PASTAN: Object to form.  
 9 A. Yes. As a process, I know I  
 10 remember that happened but I cannot  
 11 remember any specific instance and details  
 12 around that because it was a long time ago.  
 13 BY MR. PRESTON:  
 14 Q. Do you recall the PRC raising  
 15 concerns about the proposed strategy?  
 16 MR. PASTAN: Object to form.  
 17 A. I remember putting everything  
 18 through PRC and if there were any edits or  
 19 feedback we would make those changes until  
 20 it was approved and everything that was  
 21 approved was -- were the items that we used  
 22 with customers and with our internal  
 23 stakeholders.  
 24 BY MR. PRESTON:  
 25 Q. Again, give your counsel an

Page 187

1 J. Babia-Ramos  
 2 opportunity to voice an objection.  
 3 Do you recall Mr. Jimenez raising  
 4 concerns about the SOC 360 support  
 5 strategy?  
 6 MR. PASTAN: I am going to  
 7 object, Casey, and instruct the witness  
 8 not to answer that question, which  
 9 necessarily depends on any  
 10 communications that she received from  
 11 counsel. And it's privileged.  
 12 MR. PRESTON: Ms. Ramos, before  
 13 you answer or provide any information,  
 14 Nick, I am again having a hard time  
 15 hearing you.  
 16 THE WITNESS: Can you hear me  
 17 now?  
 18 MR. PASTAN: Sorry. Is this any  
 19 better?  
 20 MR. PRESTON: That's much better.  
 21 Thanks.  
 22 MR. PASTAN: This microphone, you  
 23 have to like eat it to get the sound  
 24 out of it apparently. It's on the  
 25 record.

Page 188

1 J. Babia-Ramos  
 2 MR. TORIC: Could I have the  
 3 objection either read back or stated  
 4 again. It didn't come through very  
 5 well.  
 6 MR. PASTAN: Sure. I am happy to  
 7 make it again.  
 8 Like I said, I am objecting and  
 9 instructing the witness not to answer  
 10 the question about whether Mr. Jimenez  
 11 provided certain feedback.  
 12 It necessarily depends on  
 13 communications that she received from  
 14 counsel, and it's privileged.  
 15 MR. PRESTON: Even though that  
 16 that happened within the context of a  
 17 PRC review?  
 18 MR. PASTAN: Yes. Like we  
 19 said, you guys are asking questions.  
 20 We are not putting a legal PRC  
 21 review at issue. We are not waiving  
 22 privilege. We have made this very  
 23 clear. And we have consistently  
 24 objected to this through all the  
 25 depositions.

Pages 185 to 188

Page 189

1 J. Babia-Ramos  
 2 BY MR. PRESTON:  
 3 Q. Ms. Ramos, did the promotional  
 4 review committee approve of the site 360  
 5 support strategy concept?  
 6 A. The PRC committee approved  
 7 several assets, resources, tools, content  
 8 that supported the site of care strategy.  
 9 Q. So it moved beyond the concept  
 10 stage?  
 11 Right now, we are focusing on the  
 12 concept review.  
 13 A. Right.  
 14 What are you specifically asking  
 15 was approved through the concept review?  
 16 Q. Correct.  
 17 Did the PRC approve of the SOC  
 18 360 support strategy after you submitted it  
 19 for a concept review?  
 20 A. So, again, I did not submit a  
 21 strategy. I submitted assets, programming,  
 22 content, that, within those assets and  
 23 content, supported the site of care  
 24 strategy. So they would approve the  
 25 content ultimately.

Page 190

1 J. Babia-Ramos  
 2 So whatever we used in the site  
 3 of care program was approved by PRC and so  
 4 therefore, yes. The site of care strategy  
 5 was approved.  
 6 Q. As part of the presentation of  
 7 request for approval of programming related  
 8 to the site of care 360 support strategy,  
 9 did you present information to the PRC that  
 10 concerned the independent value of the  
 11 programs beyond Remicade?  
 12 MR. PASTAN: Object to form, and  
 13 to extent it calls for a legal  
 14 conclusion.  
 15 A. So I am not familiar with that  
 16 term. So I can't answer that question.  
 17 BY MR. PRESTON:  
 18 Q. As the employee who was -- sort  
 19 of spearheaded the development of the SOC  
 20 360 support strategy, you didn't take a  
 21 look at whether this -- the programs had  
 22 any independent value beyond Remicade?  
 23 MR. PASTAN: Object to the form  
 24 of the question.  
 25 A. The content was to provide

Page 191

1 J. Babia-Ramos  
 2 information that would help health care  
 3 providers understand what the key  
 4 considerations were to infuse Remicade. So  
 5 what that meant to the practice -- you  
 6 would have to ask the practice what that  
 7 meant to them. But that was the intent of  
 8 the program and everything that was  
 9 reviewed through PRC was what we used to  
 10 support the strategy and to support the  
 11 programming.  
 12 BY MR. PRESTON:  
 13 Q. Did you provide the PRC with an  
 14 evaluation of the value of the SOC 360  
 15 programs or the benefits those programs  
 16 provided to physician practices?  
 17 MR. PASTAN: Again, object to the  
 18 form of the question.  
 19 A. Depending on what the asset was,  
 20 I mean, we would have to say what the  
 21 intent was, right. So was it education?  
 22 Was it helping the practice identify  
 23 potential barriers? So in that regard, we  
 24 provided helpful information to help  
 25 practices understand how to incorporate

Page 192

1 J. Babia-Ramos  
 2 Remicade in their daily operations.  
 3 BY MR. PRESTON:  
 4 Q. And once you received a PRC  
 5 review approval, what did you do? What was  
 6 your role, then, in implementing that  
 7 approved program or strategy?  
 8 A. So if there were edits  
 9 recommended for approval, then I would make  
 10 those edits. Once it was finally approved,  
 11 then -- again, it depends on what we are  
 12 talking about -- but the audience that it  
 13 was intended for and who was delivering the  
 14 message was also approved as part of the  
 15 PRC process, and so we would go ahead and  
 16 execute all that. Deliver that tool or  
 17 resources or whatever we are talking about  
 18 to the intended audience through the  
 19 approved modality.  
 20 Q. Was it reviewed with the PRC that  
 21 Janssen would have outside consultants  
 22 present the SOC 360 programs?  
 23 A. That was also part of the  
 24 approval process. So we would have to  
 25 indicate who was delivering the content and

Pages 189 to 192

Page 209

1 J. Babia-Ramos  
 2 would also be set forth in the submission  
 3 to the PRC?  
 4 A. That was part of the information  
 5 submitted, yes.  
 6 Q. Maybe you answered this question.  
 7 I'm sorry if I already asked it, but when  
 8 you were submitting the concept review  
 9 related to the SOC 360 programs, you  
 10 reviewed that with Mr. Jimenez as part of  
 11 the PRC review?  
 12 MR. PASTAN: I'm just going to  
 13 caution the witness to not reveal any  
 14 communications with counsel. She can  
 15 answer a question about whether  
 16 something was reviewed, but I would  
 17 limit it to that.  
 18 You can answer, if you know,  
 19 whether the concept review and  
 20 associated programs was with  
 21 Mr. Jimenez.  
 22 A. So legal is part of several  
 23 reviews along with other members of the PRC  
 24 committee.  
 25 MR. PRESTON: I'm going to mark

Page 210

1 J. Babia-Ramos  
 2 as Plaintiffs' Exhibit 140 --  
 3 MR. PASTAN: Casey, it's been  
 4 about an hour. I don't know how long  
 5 that next exhibit's going to take.  
 6 They have been taking a while.  
 7 MR. PRESTON: Yes. Let me finish  
 8 up this line of questioning, and then  
 9 we'll take a break.  
 10 I'm marking, as Plaintiffs'  
 11 Exhibit 140, an e-mail that is Bates  
 12 numbered JANSSENBIO 55-773 and the  
 13 attachment is to that was JANSSENBIO  
 14 55-774.  
 15 I don't have questions concerning  
 16 the attachment, Ms. Ramos.  
 17 (Exhibit 140, e-mail string  
 18 beginning with e-mail dated 1/10/06  
 19 with attachment bearing Production Nos.  
 20 JANSSENBIO 55-773 through 774, 13  
 21 pages, was marked for identification)  
 22 BY MR. PRESTON:  
 23 Q. I have a question regarding the  
 24 e-mail at the top of the first page of the  
 25 exhibit, an e-mail from Mr. Firriolo that

Page 211

1 J. Babia-Ramos  
 2 you were copied on and it states, "Attached  
 3 are slides that Kara wants to present  
 4 tomorrow at the Train the Trainer in prep  
 5 for the NSM. I believe this content  
 6 (Practice Support Programs, PSP), is what  
 7 was discussed (in concept) by Janice Babia  
 8 at PRC a couple of weeks ago. Edmund, I  
 9 believe you participated in that discussion  
 10 along with Freddy."  
 11 And I guess I'm showing you that  
 12 in order to see whether this refreshes your  
 13 memory that you reviewed the practice  
 14 support programs concept with Mr. Jimenez  
 15 in late 2005 or early 2006 at a PRC concept  
 16 review?  
 17 MR. PASTAN: Again, I just want  
 18 to caution the witness not to reveal  
 19 anything about what was communicated if  
 20 -- strike that.  
 21 Let me start over.  
 22 First, I just want to make it  
 23 clear. We are not waiving privilege.  
 24 I can't control what questions you ask  
 25 about this, obviously, Casey, but we

Page 212

1 J. Babia-Ramos  
 2 have made it very, very clear  
 3 throughout the entire process we are  
 4 not waiving privilege. If the witness  
 5 can answer that without revealing any  
 6 communications with counsel or any  
 7 advice of counsel, she can answer  
 8 whether a discussion was had, but I  
 9 would limit it to that if she recalls.  
 10 A. Can you ask me the question  
 11 again?  
 12 BY MR. PRESTON:  
 13 Q. Does the e-mail at the top of  
 14 Exhibit 140 refresh your memory that you  
 15 reviewed the practice support programs  
 16 concept with Mr. Jimenez in late 2005 or  
 17 early 2006 as part of a PRC concept review?  
 18 MR. PASTAN: Again, I just want  
 19 to reiterate my objection. Without  
 20 revealing any specific communications  
 21 or advice of counsel, you can answer  
 22 that question, if you recall.  
 23 A. I don't remember this e-mail,  
 24 though, I see that I'm cc'd on it, but I  
 25 did not write it. So I don't have any

Pages 209 to 212

1 J. Babia-Ramos  
 2 recollection of this e-mail and the details  
 3 around it.  
 4 BY MR. PRESTON:  
 5 Q. I am not asking for your  
 6 recollection of the specific e-mail, but  
 7 does it refresh your memory as to a meeting  
 8 with Mr. Jimenez and Mr. Greenidge  
 9 concerning the PRC concept review related  
 10 to the practice support programs?  
 11 MR. PASTAN: Again, I just want  
 12 to caution the witness not to reveal  
 13 any advice or communications with  
 14 counsel. I think she can answer what  
 15 she recalls without doing so.  
 16 Again, I don't think that this  
 17 would be anything more than what would  
 18 be revealed on a privileged log. But I  
 19 just caution her when answering the  
 20 question to keep that in mind.  
 21 A. I don't recall.  
 22 MR. PRESTON: Okay. Go off the  
 23 record.  
 24 THE VIDEOGRAPHER: The time is  
 25 2:49 p.m., and we are off the record.

1 J. Babia-Ramos  
 2 A. Okay.  
 3 (Witness reviewing document).  
 4 Q. All right. Ms. Ramos, do you  
 5 recall having a role in creating this  
 6 document?  
 7 A. Yes. I'm just nearly finished  
 8 going through. I am on slide 18.  
 9 (Witness reviewing document).  
 10 Okay.  
 11 Q. Again, according to the metadata  
 12 from this document, it's from January 2006.  
 13 Do you recall this document,  
 14 Ms. Ramos?  
 15 A. Some of the slides look familiar,  
 16 yes.  
 17 Q. Did you have play a role in  
 18 creating these slides?  
 19 A. Some of them, yes.  
 20 Q. And this presentation deck gives  
 21 an overview of the SOC 360 programming; is  
 22 that accurate?  
 23 A. It looks like it, yes.  
 24 Q. I am going to have you go to page  
 25 9 of the exhibit.

1 J. Babia-Ramos  
 2 (Recess)  
 3 THE VIDEOGRAPHER: The time is  
 4 3:02 p.m., and we are back on the  
 5 record.  
 6 MR. PRESTON: I am going to mark  
 7 as Plaintiffs' Exhibit 141 a PowerPoint  
 8 presentation that was provided in  
 9 native format. The slip cover sheet is  
 10 JANSSENBIO 52-73.  
 11 (Exhibit 141, Native File bearing  
 12 Production Nos. JANSSENBIO 52-73, 25  
 13 pages, was marked for identification)  
 14 BY MR. PRESTON:  
 15 Q. Ms. Ramos, you were identified as  
 16 the custodian of this document when it was  
 17 produced and that you were involved in  
 18 its -- you played a role in drafting it.  
 19 I will give you a moment to just  
 20 page through it again. I have a question  
 21 on a couple of the slides.  
 22 I don't want to spend too much  
 23 time on the document, but I will give you a  
 24 moment to refamiliarize yourself with it  
 25 before I ask some questions.

1 J. Babia-Ramos  
 2 A. Okay.  
 3 Q. And do you see that chart, and at  
 4 the top, it says, Site of Care 360  
 5 Programs.  
 6 And in the first box it says, "An  
 7 arsenal of programs and resources focused  
 8 on addressing Access, Efficiency and  
 9 Capacity issues to support solution selling  
 10 at every account level."  
 11 Do you see that?  
 12 A. Yes.  
 13 Q. I know we talked about the term  
 14 solution selling earlier, but does this  
 15 refresh your memory as to what solution  
 16 selling is?  
 17 A. Well, the program description  
 18 looks familiar.  
 19 Q. Do you recall what solution  
 20 selling meant?  
 21 A. I see what the slide says, but I  
 22 don't remember specifically what solution  
 23 selling meant.  
 24 Q. Was the goal to provide services  
 25 of value to site of care with respect to